July 15, 2026 —
A new study published in Gene Therapy reports that an AAV-based gene therapy designed to restore the missing FMR1 protein improved multiple disease-relevant features in a mouse model of Fragile X syndrome.
Fragile X syndrome is the most common inherited form of intellectual disability and a major single-gene condition linked to autism spectrum disorder. The disease is caused by loss or reduction of FMRP, the protein encoded by the FMR1 gene. Current treatments do not address the underlying genetic cause and instead focus on managing symptoms such as seizures, anxiety, hyperactivity, learning difficulties, and behavioral challenges.
The research team evaluated adeno-associated viral vectors engineered to deliver human FMR1 into the brain. After screening candidate vector designs, the researchers identified an approach that produced FMRP in key brain regions implicated in Fragile X syndrome.
The study was designed with translational development in mind. In addition to confirming protein expression, the researchers evaluated whether gene replacement could improve functional outcomes relevant to the disease, including seizure susceptibility, sensory activity, repetitive behavior, and electrophysiological changes.
In Fmr1 knockout mice, treatment reduced susceptibility to audiogenic seizures, a behavioral model commonly used to assess neuroexcitability in Fragile X research. The therapy also improved sensory hyperactivity and altered repetitive behaviors, including digging patterns associated with stereotypy-like activity.
Electrophysiological analysis showed normalization of elevated low-gamma EEG power, a brain activity signature that aligns with patterns observed in human Fragile X studies. The authors highlighted EEG measures as potential translational biomarkers that could help bridge preclinical and clinical development.
The work also explored key development variables, including vector design, promoter selection, dosing strategies, and delivery routes. Cincinnati Children’s collaborators and Forge Biologics investigators reported that two administration pathways may be combined to improve coverage across brain targets, a factor that could be important for future clinical translation.
The researchers noted that benefits were observed when therapy was administered at developmental stages corresponding to different human developmental windows. This suggests that some Fragile X-related features may remain modifiable beyond the earliest stages of life, although further research is needed to understand therapeutic timing and durability.
The findings remain preclinical, and the therapy has not yet been tested in humans. Future work will need to address manufacturing, safety, biodistribution, immune response, dosing, and long-term expression before clinical studies can be considered.
While the results do not change current clinical care, the study provides further evidence that restoring FMRP may be biologically meaningful and therapeutically relevant across multiple Fragile X traits. The data support continued investigation of AAV-mediated FMR1 gene replacement as a potential disease-modifying strategy for Fragile X syndrome.
